SCHEMBL13234466

SCHEMBL13234466

CC(C)(C)c1cc(NC(=O)NCc2cccc(Cl)c2)no1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
HTT P42858 3/20 0.58
ATM Q13315 1/20 0.58
MAPK14 Q16539 3/20 0.57
KMT2A Q03164 3/20 0.56
RAB9A P51151 3/20 0.56
MEN1 O00255 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
NPC1 O15118 2/20 0.54
FLT3 P36888 4/20 0.54
GAA P10253 1/20 0.53
RAF1 P04049 3/20 0.52
EGFR P00533 1/20 0.51
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
EPHX2 P34913 1/20 0.49
MAPK13 O15264 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13234464 0.84 RAF1 (0.62) MAPTHTTMAPK14KMT2ARAB9A
SCHEMBL13234449 0.81 KMT2A (0.74) MAPTHTTATMMAPK14KMT2A
SCHEMBL101749 0.80 RAF1 (0.64) MAPK14RAF1MAPK13MAPK12MAPK11
SCHEMBL13234563 0.79 RAF1 (0.61) MAPK14KMT2ARAB9AMEN1NPC1
SCHEMBL2944830 0.78 RAF1 (0.66) MAPTHTTMAPK14KMT2ARAB9A
SCHEMBL13234463 0.77 RAB9A (0.64) MAPTHTTMAPK14KMT2ARAB9A
SCHEMBL13620456 0.76 EGFR (0.61) MAPTHTTATMMAPK14KMT2A
SCHEMBL2951112 0.75 RAB9A (0.77) MAPTHTTATMMAPK14KMT2A
SCHEMBL11017752 0.75 EGFR (0.69) MAPTHTTATMMAPK14KMT2A
SCHEMBL13200637 0.75 FLT3 (0.54) FLT3EGFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS ABL1, ABL2, BCR MAPT 1165/4885HTT 1491/4885ATM 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.